Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®) in Advanced Unresponsive Cancer

Authors

Joseph B. Zwischenberger, Department of Surgery, University of Kentucky, Lexington, USAFollow
Peyton Skaggs, College of Medicine, University of Kentucky, Lexington, USAFollow
Katherine Breetz, College of Medicine, University of Kentucky, Lexington, USAFollow
Jan Winetz, Verthermia Acquisitions, Inc., Henderson, USAFollow
Roger Vertrees, Verthermia Acquisitions, Inc., Henderson, USAFollow

Abstract

Hyperthermia has been utilized for cancer therapy, including metastatic cancer, for decades with isolated success. Previous research has indicated that the elevated temperature of 42°C induces cell death, apoptosis, or senescence of responsive cancers, providing a mechanism for tumor destruction and management. Veno-venous perfusion-induced systemic hyperthermia (V-V PISH) may be the key to improving advanced tumor responsiveness to previously failed chemotherapy and/or radiation as combination therapy. The most recent iteration of V-V PISH, Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®), provides homogeneous heating of all tissues with electrolyte and pH control and continues to prove safe and effective. The utilization of HEATT® in advanced, unresponsive cancers should be further explored as a part of integrative oncology care.

Recommended Citation

Zwischenberger, Joseph B.; Skaggs, Peyton; Breetz, Katherine; Winetz, Jan; and Vertrees, Roger (2023) "Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®) in Advanced Unresponsive Cancer," Journal of Shock and Hemodynamics: Vol. 2(1) :E2023211 DOI: https://doi.org/10.57905/josh/e2023211

Available at: https://digitalcommons.library.tmc.edu/josh/vol2/iss1/1